Nuvectis Pharma, Inc. Common Stock (NVCT) is a publicly traded Healthcare sector company. As of May 21, 2026, NVCT trades at $10.63 with a market cap of $275.87M and a P/E ratio of -7.99. NVCT moved +3.11% today. Year to date, NVCT is +24.62%; over the trailing twelve months it is -0.19%. Its 52-week range spans $4.44 to $13.34. Analyst consensus is buy with an average price target of $13.50. Rallies surfaces NVCT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Nuvectis Pharma Q1 Cash Falls to $25.1M, Net Loss Widens to $6.1M: Nuvectis Pharma closed Q1 with $25.1 M in cash, down from $31.6 M at year-end, and posted a $6.1 M net loss, up $0.8 M year-over-year, driven by increased R&D and G&A spending. Its NXP900 Phase 1b trial is enrolling monotherapy and sotorasib combination arms and expects preliminary data this summer after preclinical synergy results.
| Metric | Value |
|---|---|
| Price | $10.63 |
| Market Cap | $275.87M |
| P/E Ratio | -7.99 |
| EPS | $-1.32 |
| Dividend Yield | 0.00% |
| 52-Week High | $13.34 |
| 52-Week Low | $4.44 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-26.44M |
| Gross Margin | 0.00% |
2 analysts cover NVCT: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $13.50.